The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

Launched by JASPER GERRITSEN · Nov 1, 2023

Keywords

ClinConnect Summary

The SUPRAMAX Study is researching the effects of two different surgical approaches for treating patients with high-grade gliomas, which are aggressive types of brain tumors. Specifically, the study compares "supramaximal resection" (SMR), which involves removing more of the tumor, including parts that are not clearly visible on scans, versus "maximal resection," which focuses only on the visible tumor. The goal is to see if removing more of the tumor can lead to better survival rates and improved quality of life for patients. The study will also look at how well patients recover after surgery and which patients may benefit the most from this approach.

To participate in the trial, patients need to be between 18 and 90 years old and have a confirmed diagnosis of high-grade glioma. They must also be able to provide informed consent. The study is currently recruiting participants and is being conducted at various medical centers across Europe and North America. Patients who join the study can expect to undergo surgery and will be monitored over several months to track their recovery and overall health. It's important for patients to know that this research aims to improve treatment options for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years and ≤90 years
• • 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
• • 3. Written informed consent
• Exclusion Criteria:
• • 1. Tumors of the cerebellum, brainstem or midline
• • 2. Multifocal contrast enhancing lesions
• • 3. Medical reasons precluding MRI (e.g. pacemaker)
• • 4. Inability to give written informed consent
• • 5. Secondary high-grade glioma due to malignant transformation from low-grade glioma
• • 6. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin